Camber Launches Chlorzoxazone Tablets, USP
Piscataway, NJ, April 29, 2025 –Camber Pharmaceuticals is excited to announce the addition of Chlorzoxazone Tablets, USP.
Chlorzoxazone Tablets, USP are indicated as an adjunct to rest, physical therapy, and other measures for the relief of discomfort associated with acute, painful musculoskeletal conditions.
Chlorzoxazone 250 mg Tablets, USP are available in 60 count bottles.
To find out more information on Chlorzoxazone Tablets, USP, please visit: www.camberpharma.com/chlorzoxazone
Camber Pharmaceuticals is a fully integrated pharmaceutical company. Its parent company, Hetero, of Hyderabad, India, is one of the world’s leading API and finished dose manufacturers. Camber is committed to bringing the highest quality generic pharmaceuticals to consumers and improving quality of life through cost-effective medications.
Recent articles
- New to Camber’s Portfolio: Olmesartan medoxomil, Amlodipine and Hydrochlorothiazide Tablets
- Camber Pharmaceuticals Honored as Second Merit Finalist at 2026 DIANA Awards
- Camber Launches Nitazoxanide Tablets
- Cisatracurium Besylate Injection, USP Added to Camber’s Portfolio
- Camber Welcomes Summer 2026 Intern Class
- Camber Launches 5 Generics in May






